• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

C端Src同源激酶用于抑制Src家族激酶活性的一种新型非催化机制。

A novel non-catalytic mechanism employed by the C-terminal Src-homologous kinase to inhibit Src-family kinase activity.

作者信息

Chong Yuh-Ping, Mulhern Terrence D, Zhu Hong-Jian, Fujita Donald J, Bjorge Jeffrey D, Tantiongco John-Paul, Sotirellis Nikolaos, Lio Daisy Sio Seng, Scholz Glen, Cheng Heung-Chin

机构信息

Department of Biochemistry and Molecular Biology, University of Melbourne, Parkville, Victoria 3010, Australia.

出版信息

J Biol Chem. 2004 May 14;279(20):20752-66. doi: 10.1074/jbc.M309865200. Epub 2004 Feb 25.

DOI:10.1074/jbc.M309865200
PMID:14985335
Abstract

Although C-terminal Src kinase (CSK)-homologous kinase (CHK) is generally believed to inactivate Src-family tyrosine kinases (SFKs) by phosphorylating their consensus C-terminal regulatory tyrosine (Tyr(T)), exactly how CHK inactivates SFKs is not fully understood. Herein, we report that in addition to phosphorylating Tyr(T), CHK can inhibit SFKs by a novel non-catalytic mechanism. First, CHK directly binds to the SFK members Hck, Lyn, and Src to form stable protein complexes. The complex formation is mediated by a non-catalytic Tyr(T)-independent mechanism because it occurs even in the absence of ATP or when Tyr(T) of Hck is replaced by phenylalanine. Second, the non-catalytic CHK-SFK interaction alone is sufficient to inactivate SFKs by inhibiting the catalytic activity of autophosphorylated SFKs. Third, CHK and Src co-localize to specific plasma membrane microdomains of rat brain cells, suggesting that CHK is in close proximity to Src such that it can effectively inactivate Src in vivo. Fourth, native CHK.Src complex exists in rat brain, and recombinant CHK.Hck complex exists in transfected HEK293T cells, implying that CHK forms stable complexes with SFKs in vivo. Taken together, our findings suggest that CHK inactivates SFKs (i) by phosphorylating their Tyr(T) and (ii) by this novel Tyr(T)-independent mechanism involving direct binding of CHK to SFKs. It has been documented that autophosphorylated SFKs can still be active, in some cases even when their Tyr(T) is phosphorylated. Thus, the ability of the Tyr(T)-independent mechanism to suppress the activity of both non-phosphorylated and autophosphorylated SFKs represents a fail-safe measure employed by CHK to down-regulate SFK signaling under all circumstances.

摘要

尽管一般认为C端Src激酶(CSK)同源激酶(CHK)通过磷酸化Src家族酪氨酸激酶(SFK)的共有C端调节性酪氨酸(Tyr(T))使其失活,但CHK究竟如何使SFK失活尚未完全清楚。在此,我们报告,除了磷酸化Tyr(T)外,CHK还可通过一种新的非催化机制抑制SFK。首先,CHK直接与SFK成员Hck、Lyn和Src结合形成稳定的蛋白质复合物。复合物的形成由一种非催化的不依赖Tyr(T)的机制介导,因为即使在没有ATP的情况下或当Hck的Tyr(T)被苯丙氨酸取代时也会发生。其次,单独的非催化CHK-SFK相互作用就足以通过抑制自身磷酸化的SFK的催化活性使SFK失活。第三,CHK和Src共定位于大鼠脑细胞的特定质膜微结构域,这表明CHK与Src紧密相邻,从而能够在体内有效使Src失活。第四,天然的CHK.Src复合物存在于大鼠脑中,重组的CHK.Hck复合物存在于转染的HEK293T细胞中,这意味着CHK在体内与SFK形成稳定的复合物。综上所述,我们的研究结果表明,CHK使SFK失活的方式为:(i)通过磷酸化其Tyr(T);(ii)通过这种新的不依赖Tyr(T)的机制,即CHK与SFK直接结合。据记载,自身磷酸化的SFK在某些情况下即使其Tyr(T)被磷酸化仍可能具有活性。因此这种不依赖Tyr(T)的机制抑制非磷酸化和自身磷酸化SFK活性的能力,代表了CHK在所有情况下下调SFK信号传导所采用的一种安全保障措施。

相似文献

1
A novel non-catalytic mechanism employed by the C-terminal Src-homologous kinase to inhibit Src-family kinase activity.C端Src同源激酶用于抑制Src家族激酶活性的一种新型非催化机制。
J Biol Chem. 2004 May 14;279(20):20752-66. doi: 10.1074/jbc.M309865200. Epub 2004 Feb 25.
2
Csk-homologous kinase (Chk) is an efficient inhibitor of Src-family kinases but a poor catalyst of phosphorylation of their C-terminal regulatory tyrosine.Csk 同源激酶(Chk)是Src 家族激酶的有效抑制剂,但对其 C 末端调节性酪氨酸的磷酸化催化作用较差。
Cell Commun Signal. 2017 Aug 7;15(1):29. doi: 10.1186/s12964-017-0186-x.
3
C-terminal Src kinase (CSK) and CSK-homologous kinase (CHK)--endogenous negative regulators of Src-family protein kinases.C端Src激酶(CSK)和CSK同源激酶(CHK)——Src家族蛋白激酶的内源性负调控因子。
Growth Factors. 2005 Sep;23(3):233-44. doi: 10.1080/08977190500178877.
4
C-terminal Src kinase-homologous kinase (CHK), a unique inhibitor inactivating multiple active conformations of Src family tyrosine kinases.C端Src激酶同源激酶(CHK),一种使Src家族酪氨酸激酶的多种活性构象失活的独特抑制剂。
J Biol Chem. 2006 Nov 3;281(44):32988-99. doi: 10.1074/jbc.M602951200. Epub 2006 Sep 7.
5
Endogenous and synthetic inhibitors of the Src-family protein tyrosine kinases.Src家族蛋白酪氨酸激酶的内源性和合成抑制剂。
Biochim Biophys Acta. 2005 Dec 30;1754(1-2):210-20. doi: 10.1016/j.bbapap.2005.07.027. Epub 2005 Sep 8.
6
Defining the substrate specificity determinants recognized by the active site of C-terminal Src kinase-homologous kinase (CHK) and identification of β-synuclein as a potential CHK physiological substrate.定义 C 端Src 激酶同源激酶(CHK)活性位点识别的底物特异性决定因素,并鉴定β-突触核蛋白为潜在的 CHK 生理底物。
Biochemistry. 2011 Aug 9;50(31):6667-77. doi: 10.1021/bi2001938. Epub 2011 Jul 18.
7
Structural elements and allosteric mechanisms governing regulation and catalysis of CSK-family kinases and their inhibition of Src-family kinases.调控和催化CSK家族激酶及其对Src家族激酶抑制作用的结构元件和变构机制。
Growth Factors. 2010 Oct;28(5):329-50. doi: 10.3109/08977194.2010.484424.
8
Development of the procedures for high-yield expression and rapid purification of active recombinant Csk-homologous kinase (CHK): comparison of the catalytic activities of CHK and CSK.活性重组Csk同源激酶(CHK)的高产表达及快速纯化方法的建立:CHK与CSK催化活性的比较
Protein Expr Purif. 2010 Dec;74(2):139-47. doi: 10.1016/j.pep.2010.07.007. Epub 2010 Jul 25.
9
Interplay between the tyrosine kinases Chk and Csk and phosphatase PTPRJ is critical for regulating platelets in mice.酪氨酸激酶 Chk 和 Csk 与磷酸酶 PTPRJ 之间的相互作用对于调节小鼠血小板至关重要。
Blood. 2020 Apr 30;135(18):1574-1587. doi: 10.1182/blood.2019002848.
10
Purification of bovine thymus cytosolic C-terminal Src kinase (CSK) and demonstration of differential efficiencies of phosphorylation and inactivation of p56lyn and pp60c-src by CSK.牛胸腺胞质C端Src激酶(CSK)的纯化以及CSK对p56lyn和pp60c-src磷酸化和失活的不同效率的证明。
Biochemistry. 1996 Sep 10;35(36):11874-87. doi: 10.1021/bi9603940.

引用本文的文献

1
CD133-Dependent Activation of Phosphoinositide 3-Kinase /AKT/Mammalian Target of Rapamycin Signaling in Melanoma Progression and Drug Resistance.CD133 依赖性激活磷酸肌醇 3-激酶/AKT/雷帕霉素靶蛋白信号通路在黑色素瘤进展和耐药中的作用。
Cells. 2024 Jan 26;13(3):240. doi: 10.3390/cells13030240.
2
MMP-2 regulates Src activation via repression of the CHK/MATK tumor suppressor in osteosarcoma.基质金属蛋白酶-2通过抑制骨肉瘤中的CHK/MATK肿瘤抑制因子来调节Src激活。
Cancer Rep (Hoboken). 2023 Dec 8;7(2):e1946. doi: 10.1002/cnr2.1946.
3
Regulation, targets and functions of CSK.
CSK的调控、靶点及功能。
Front Cell Dev Biol. 2023 Jun 16;11:1206539. doi: 10.3389/fcell.2023.1206539. eCollection 2023.
4
Dissection of the catalytic and regulatory structure-function relationships of Csk protein tyrosine kinase.Csk蛋白酪氨酸激酶的催化和调节结构-功能关系剖析
Front Cell Dev Biol. 2023 Mar 1;11:1148352. doi: 10.3389/fcell.2023.1148352. eCollection 2023.
5
Regulation, targets and functions of CHK.CHK的调控、靶点及功能
Front Cell Dev Biol. 2022 Dec 9;10:1068952. doi: 10.3389/fcell.2022.1068952. eCollection 2022.
6
CSK-homologous kinase (CHK/MATK) is a potential colorectal cancer tumour suppressor gene epigenetically silenced by promoter methylation.CSK 同源激酶 (CHK/MATK) 是一个潜在的结直肠癌肿瘤抑制基因,其启动子甲基化导致其表观遗传沉默。
Oncogene. 2021 Apr;40(17):3015-3029. doi: 10.1038/s41388-021-01755-z. Epub 2021 Mar 25.
7
Regulation of Src Family Kinases during Colorectal Cancer Development and Its Clinical Implications.结直肠癌发生过程中Src家族激酶的调控及其临床意义
Cancers (Basel). 2020 May 23;12(5):1339. doi: 10.3390/cancers12051339.
8
Early emergence of negative regulation of the tyrosine kinase Src by the C-terminal Src kinase.C末端Src激酶对酪氨酸激酶Src的负调控早期出现。
J Biol Chem. 2017 Nov 10;292(45):18518-18529. doi: 10.1074/jbc.M117.811174. Epub 2017 Sep 22.
9
Csk-homologous kinase (Chk) is an efficient inhibitor of Src-family kinases but a poor catalyst of phosphorylation of their C-terminal regulatory tyrosine.Csk 同源激酶(Chk)是Src 家族激酶的有效抑制剂,但对其 C 末端调节性酪氨酸的磷酸化催化作用较差。
Cell Commun Signal. 2017 Aug 7;15(1):29. doi: 10.1186/s12964-017-0186-x.
10
Hematopoietic cell kinase (HCK) as a therapeutic target in immune and cancer cells.造血细胞激酶(HCK)作为免疫细胞和癌细胞的治疗靶点。
Oncotarget. 2015 Jun 30;6(18):15752-71. doi: 10.18632/oncotarget.4199.